As ITP in dogs is largely analogous to ITP in humans, we questioned whether human TPO agents such as the Food and Drug Administration (FDA) approved human TPO-R agonists can be used as a new therapeutic measure in dogs with ITP that cannot be controlled by standard therapy. Here, MPL is linked to autoimmune thrombocytopenic purpura.